314: JD Vance's biotech ties, Cassava resignations, and insulin shortages
The Readout Loud
00:00
Intro
The chapter covers the latest updates in the biotech industry, focusing on JD Vance's potential influence on healthcare policies, shortages of insulin by Novo Nordisk and Eli Lilly, as well as ongoing developments regarding Cassava's Alzheimer's drug. Additionally, the team discusses STAT's election coverage and concludes with an advertisement for insights from health and medicine leaders at STAT's flagship event.
Transcript
Play full episode
